Study finds Ozempic users judged more harshly than diet-and-exercise users

In a randomized experiment with 297 participants, a woman described as losing weight with the medication Ozempic was viewed more negatively and assumed to be less healthy than a woman described as losing the same weight through diet and exercise alone ^[1].

The study appears in the October 2026 issue of Social Science & Medicine, published by Elsevier ^[1]. Its authors, Madelyn H. Rosenthal and Mary S. Himmelstein, write that until now no research had directly tested whether attitudes toward a person differ when that person had bariatric surgery rather than used a weight-loss drug ^[1]. Prior work, they note, has found that people who have bariatric surgery face prejudice tied both to their body and to the surgery itself, which is sometimes described as taking the easy way out ^[1].

Participants were 78.8% women, averaged 20.2 years old, and 42.4% had a body mass index above 25.0 kg/m2 ^[1]. Each was randomly assigned to read one of three vignettes about a woman named Alex ^[1]. In every version, Alex lost weight and later regained it. Only the method differed: bariatric surgery, a common weight-loss medication (Ozempic), or behavioral modification, meaning diet and exercise alone ^[1]. Participants then answered questionnaires about their attitudes toward Alex, toward weight, and toward weight-loss strategies ^[1].

Alex was rated more negatively and assumed to be less healthy when she used Ozempic rather than diet and exercise alone ^[1]. Ratings for the bariatric surgery version did not differ significantly from either of the other two methods ^[1]. The published highlights state that "Ozempic users are viewed less favorably relative to diet/exercise users" ^[1].

The researchers also reported that participants drastically underestimated how common weight regain is and misjudged how effective different weight management strategies are ^[1]. They conclude that the findings point to a need for better, evidence-based public information about body weight and for ways to reduce weight stigma ^[1].

Some limits are worth noting. The sample was young and mostly women, so the results describe how that group responded ^[1]. The experiment tested a single medication, named in the vignette as Ozempic, which is semaglutide. Other GLP-1 medications such as Wegovy and Rybelsus, and tirzepatide drugs including Mounjaro and Zepbound, were not part of the study, so whether the same judgments would attach to them has not been tested ^[1]. The authors report no conflicts of interest and say the research received no specific grant funding; the underlying data will be made available on request ^[1].

Why it matters for patients

The researchers describe what they call compounding stigma: negative judgment tied both to a person's body and to how that person treated it ^[1]. The experiment isolated the method of weight loss. In all three versions, Alex lost weight and then regained it, yet only the medication version drew more negative ratings and assumptions of poorer health ^[1].

The paper's highlights say that lay people poorly understand both the prevalence of weight regain and how well different weight strategies work ^[1]. For anyone taking a GLP-1 drug, that combination matters: a common outcome such as regaining weight after stopping treatment may be read by others as a personal failing rather than a typical pattern, and the drug itself may color how a person is seen regardless of results ^[1].

The study measured attitudes, not behavior. It did not test whether these ratings change how people treat someone in real settings such as work, dating or medical care, and that question has not been answered here ^[1].

What happens next

The paper calls for empirically informed public health information about body weight and for strategies to mitigate weight stigma ^[1]. No follow-up study, public health campaign or policy change tied to these findings has been reported.